Editas Medicine, Inc.
EDIT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650664
In the last 90 days, Editas Medicine, Inc. insiders filed 0 open-market purchases and 5 sales; 215 institutions reported holding it in 13F filings for Q2 2026, worth $386.3M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Editas Medicine, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Of which not filed for Q1 2023 | Q1 2023 | Change |
|---|---|---|---|---|
| Holders | 251 | 3 | 236 | −12 |
| Shares | 54.0M | 14.2K | 52.4M | −1.62M (−3.0%) |
| Value | $479.3M | $125.7K | $384.0M | −$95.2M (−19.9%) |
3 institutions that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (30)
Institutions that held Editas Medicine, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
Sold out (42)
Institutions that held Editas Medicine, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
Not filed for Q1 2023 yet (3)
Institutions that held Editas Medicine, Inc. at the end of Q4 2022 and haven't filed a 13F for Q1 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Keystone Financial Group | 14,000 | $124.2K |
| Sargent Bickham Lagudis LLC | 100 | $887 |
| CoreCap Advisors, LLC | 73 | $648 |